BRIEF-China FDA approves country's first all-oral regimen for chronic Hepatitis C
April 28 Bristol-myers Squibb Co
* China FDA approves country's first all-oral regimen for chronic Hepatitis C, daklinza (daclatasvir) in combination with sunvepra (asunaprevir)
* Bristol-Myers Squibb Co - daklinza also approved in China for use in combination with other agents, including sofosbuvir, for HCV genotypes 1-6
* Bristol-Myers Squibb Co - sofosbuvir is under review by China food and drug administration and is not currently licensed in China Source text for Eikon: Further company coverage: